The study of prethymic stages of T cell development has been limited because specific markers for mouse pro-T lymphocytes were not available. We developed a panel of rat monoclonal antibodies (mAbs) that bind to our pro -T lymphocyte clones obtained from bone marrow of young adult mice and the thymus of 14-d-old embryos. The mAbs, called Joro 30-8, Joro 37-5, and Joro 75, were found to bind to all pro -T clones tested but not to cell lines representing later stages of T cell development, B lymphocyte, or myeloid lineages . We determined the frequency and tissue distribution in normal and immunodeficient mouse strains as well as the ontogeny in liver and thymus of cells positive for these mAbs. The results were consistent with the pattern of reactivity observed with cell lines. We isolated Joro 30-8+, Joro 37-5+, and Joro 75+ bone marrow cells by cell sorter and found that: (a) phenotypically, they are Thy-1+, CD4 -, CD8 -, CD3-, B-220-, IgM-, F4/80-, and PgP-1+; (b) they grew in response to the combination of interleukin 3 (IIr3) + IIr4 or IIr3 + IIr4 + IIr6; and (c) Joro 37-5+ and Joro 75+ marrow cells gave rise to mature T lymphocytes but not to B lymphocytes, while Joro 30-8+ marrow cells generated both T and B lymphocytes after 8-12 wk of transfer into severe combined immunodeficient (Scid) mice. In normal mice subjected to 600 rad of irradiation to induce a wave of thymus recolonization, we found by flow fluorocytometry analysis that Joro+ cells entered the thymus 2 d after irradiation, expanded during the next 4 d, and underwent further differentiation, and from day 8 up to day 21, post-irradiation Joro+ cells were no longer detectable in the thymuses. Immunohistochemical analysis of normal thymus shows the presence of very few Joro 30-8+, Joro 37-5+, and Joro 75+ lymphoid cells in the subcapsular area and outer cortex but not in the medulla . The kinetic analysis of tissue sections from thymuses at various days post-irradiation suggests that Joro+ cells enter the thymus via blood vessels through the subcapsular and outer cortex areas; subsequently, these cells seem to migrate to the inner cortex without reaching the medulla, and give rise to Joro thymocytes. We conclude that in bone marrow of young mice, cells expressing Joro 30-8 are very early hematopoietic precursor cells that are either committed to the lymphocyte pathway or are even less differentiated pluripotent cells. Commitment to T cell differentiation appears to be associated with additional expression of Joro 37-5 and Joro 75. D uring mouse development, hematopoietic precursor cells from fetal liver colonize the thymus ; in postnatal life, the thymus is seeded by precursor cells from the bone marrow (1-4). The immigrant precursors proliferate and differentiate in this environment, giving rise to thymocytes and eventually to functional peripheral T lymphocytes. The process of T cell differentiation within the thymus has been studied by cell surface phenotyping and the analysis of TCR gene rearrangements (5-10). However, the study of prethymic stages ofT cell development has been limitedbecause specific markers for mouse T cell progenitors were not available. Recently, it has been found that a small population of bone marrow cells (0.1-0.3%) expressing Thy-1 and Sca-1 surface antigens, and lacking surface markers expressed by T and B lymphocytes or myeloid cells, possessed thymus-repopulating potential (11). However, neither Thy-1 nor Sca-1 are specific markers for T cell progenitors and/or pluripotent stem cells (12, and our unpublished results) .
D
uring mouse development, hematopoietic precursor cells from fetal liver colonize the thymus ; in postnatal life, the thymus is seeded by precursor cells from the bone marrow (1) (2) (3) (4) . The immigrant precursors proliferate and differentiate in this environment, giving rise to thymocytes and eventually to functional peripheral T lymphocytes. The process of T cell differentiation within the thymus has been studied by cell surface phenotyping and the analysis of TCR gene rearrangements (5) (6) (7) (8) (9) (10) . However, the study of prethymic stages ofT cell development has been limitedbecause specific markers for mouse T cell progenitors were not available. Recently, it has been found that a small population of bone marrow cells (0.1-0.3%) expressing Thy-1 and Sca-1 surface antigens, and lacking surface markers expressed by T and B lymphocytes or myeloid cells, possessed thymus-repopulating potential (11) . However, neither Thy-1 nor Sca-1 are specific markers for T cell progenitors and/or pluripotent stem cells (12, and our unpublished results) .
Over the last 5 yr, we have established several T cell progenitor clones from the bone marrow of young adult mice and the thymus of 14-d-old mouse embryos . These clones represent the two earliest stages of T cell development identified so far. We call them "marrow-type" and "thymustype" proT lymphocytes (reviewed in reference 13) . Both types of clones contain the TCR a, (3, y, and S genes in the germline configuration. Thymus-type clones express mRNA from the CD3y, but not from the CD36 or CD3e genes. Both types of proT clones are Thy-1+ Sca-1-. Marrow-type clones grow in vitro in the presence of IL3 and IL4, and thymustype clones grow in IL2 or 114 (14) (15) (16) (17) . Both types of clones generate in vitro all major subsets of thymocytes, including cells expressing TCR-a/ß-CD3, and cells expressing TCRy/S-CD3 receptor complexes on the cell membrane, if they are cultured in the presence of thymic epithelial cells (18) .
We have developed a panel of rat mAbs against these clones in order to be able to identify these cells in vivo, to isolate them, and to study their functional properties . Three mAbs (Joro 30-8, Joro 37-5, andJoro 75) that were specific for unique cell surface determinants of early T cell progenitors were studied in detail and are the subject of the present report .
Materials and Methods
Animals. BALB/c, C57BL/6, and CBA/J normal female mice (3-12 wk old) were from IFFA Credo (Saint-Germain, France). BALB/c and C57BL/6 nu/nu mice (6-8 wk old) were from Bomholgard (Ry, Denmark) . (NIH Swiss II nu/nu x CBA/N)F, (xid/nu) female (6-8 wk old) mice, C.B. 17 Scid, and AKR Scid (6-12 wk old) mice are bred and housed in sterile isolators in the animal barrier facility of our institute. Scid mice without detectable serum Ig were used . C57BL/6 pregnant mice were from our breeding facility. The day of detection of vaginal plug was considered day 0 of gestation.
Cell Preparation. Cell suspensions were prepared free of erythrocytes from thymus, spleen, lymph nodes, bone marrow, and fetal liver, as described (14, 19, 20) . Cells were washed and resuspended in appropriate buffer or culture medium (IMDM + 5% FCS + 2-ME [5 x 10-5 M], L-glutamine [2 mM], gentamycin [50 lAg/ml]) at the desired concentrations .
Cell Lines. Growth factor-dependent lines included bone marrow proT lymphocyte clones (C4-77, C4-86, C4-95) (14) ; fetal thymocyte clones (FTH5, FTFI, FTA2, FTG12, FTH12, FTD11) (16, 17) ; bone marrow pro-B lymphocyte clones (CB/Bm7, BC/ Bmll, LyD9, LyH7) (19, 20) ; CD8-CD4-TCR-ci/ß-CD3' LD1 T cell line (21) ; myeloid progenitor bone marrow clone Mye-5 (established with IL3 from bone marrow of CBA/j mice) (Palacios, R., unpublished results) ; IL3-dependent mast cell line (3213c1) (22) ; 11,2-dependent cytolytic T cell lines (CTLL, CFLI) (23, 24) ; and Th cell line HT-2 (25) . Tumor cell lines included thymic lymphomas BW5147, EIL4; fetal liver pre-B cell lymphoma CgC (provided by S. Carson, Basel Institute for Immunology, Basel) ; marrow pre-B cell lymphomas (18.81, 40E1, 70Z/3) ; B cell lymphomas (BCL1, WEHI-279, WEH1231) ; macrophage cell line (P388D1) ; mastocytoma (P815), myelomonocytic leukemia (WEHI-3), fibroblast lines (L, 3T3) .
Development ofJoro Hybridomas. Two Lewis rats were injected each with 2 x 10' C4-77 proT cells (emulsified in CFA) in the right hind foot pad. 3 d later, 2 x 10 7 C4-77 cells were injected (without adjuvant) in the same foot pad. 4 d after the second injection, 2 x 10' C4-77 cells (without adjuvant) were injected again in the same region . On the next day, the regional lymph nodes from one of the rats were obtained, cell suspensions were prepared, and fused with the Ag8.653 myeloma cells as described (26) . Supernatants from wells clearly containing growing hybridoma cells were tested by flow fluorocytometry (FM)' analysis for reactivity ' Abbreviation used in this paper: FM, flow fluorocytometry.
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Pro-T lymphocytes with the C4-77 proT lymphocyte clone. Supernatants that scored positive on these cells were subsequently screened on a pro-B lymphocyte clone (CB/Bm7), a pre-B cell lymphoma (18.81), a macrophage line (P388D1), total thymocytes from adult mice, and 15-d fetal liver mononuclear cells from CB57BL/6 embryos. Aliquots of all theseJoro hybridomas were frozen . Three hybridomas called Joro 30-8, Joro 37-5, and Joro 75 were selected for further study. They were recloned twice by limiting dilution (0 .5 cells/well) in culture medium supplemented with IL-6 . The class of rat Ig produced by the hybridomas was determined by ELISA with a commercially available kit (Amersham Corp., Arlington Heights, IL). Joro 30-8-, Joro 37-5-, andJoro 75-purified mAbs were conjugated to biotin-N-hydroxysuccinimide, as described before (27) . Outer Antibodies . Biotin-or FITC-conjugated antibodies were used against: B-220 (hybridoma 14 .8), IgM'j (hybridoma RS3.1), CD3 (hybridoma 145-C11), Thy-1.2 (hybridoma 30H12), CD8 (hybridoma 5367.2), CD4 (hybridoma GK1.5). FITC-LyT2 and PE-L3T4 were purchased from Becton Dickinson & Co . (Mountain View, CA). The following antibodies were used in the form of hybridoma culture supernatant : jlld, B-220 (hybridoma RA3-3A1), M5/114 (IA, IE), PgP-1, (142/5), GM1.2 (granulocytes), and F4/80 (macrophages). The reports describing the development and characterization of these mAbs are listed elsewhere (14, 19, 20, 27 (28) and tested for biologic activity in proliferative assays, as described (20, 29) , were used . 1 U of activity was considered to the dilution of the supernatant given half of the maximal responses. rII,,7 (30) was a kind gift of Dr. S. Gillis (Immunex Corp., Seattle, WA).
Puriftcadon ofJoro' Bone Marrow Cells. Bone marrow cells from 3-wk-old CBA/J mice were depleted of B-220*, jlld*, la', and GM1.2' cells by treatment with a mixture of cytotoxic mAbs (RA3-3A1, j11d, M5/114, GM1.2) and complement as described (14, 20, 27) . This treatment killed 91-98% nucleated bone marrow cells, as assessed by trypan blue dye test . Purification of Joro 30-8', Joro 37-5', or Joro 75' marrow cells was carried out by cell sorter (FRCS 440; Becton Dickinson & Co.) using biotin-labeled Joro mAbs and FITC-streptavidin (27) . After completion of the cell sort, a fraction of the sorted cells were reanalyzed to assess the degree of purification obtained . The results reported here are from experiments performed with marrow cell preparations in which the highest degree of purification (99.0-99.5%) could be obtained (see also Results and Discussion) .
Assay for Cell Proliferation. Cell sorter-purified Joro 30-8', Joro 37-5', and Joro 75' marrow cells were cultured at 5 x 103 cells/well in round-bottomed microplates (Nunc, Roskilde, Denmark) containing saturating concentrations of the various ILs (100 U/ml) (from rILlß to rIIr7) either alone or in several combinations in a final volume of 200 A.1 of culture medium . Cultures in triplicate were incubated at 37°C, and cell growth was assessed both visually (with an inverted microscope) and by Assays for Functional Pbtential ofJoro* Cells. AKR scid mice exposed to 350 rad (140 rad/min) of y rays (gamma cell 40; Atomic Energy of Canada Ltd ., Ontario) 20-24 h before were injected intravenously with cell sorter-purified Joro* marrow cells (2-2.5 x UP cells/0.4 ml PBS/mouse) or PBS alone (controls). Before injection into mice, the cell sorter-purified Joro* marrow cells were incubated in culture medium supplemented with rIL3 + rIL4 at 37°C for 12 h to allow shedding of bound antibodies . Mice were kept in cages with individual sterile filters in sterile isolators and were fed with sterile food and water containing antibiotics.
In the experiments carried out to assess thymus recolonization potential of Joro* cells, C57BL/6 mice were exposed to 600 rad of .y rays (140 rad/min) to induce a wave of thymus recolonization. The presence ofJoro 30-8*, Joro 37-5*, and Joro 75* cells in either thymocyte cell suspensions was assessed by FM analysis daily during 21 d using biotin-labeled Joro antibodies and FITCstreptavidin, or in thymic tissue, sections were determined by immunoperoxidase staining (see below) . Three mice were studied at each time point.
FM Analysis. Immunofluorescence staining and FM analysis was performed with a FACScan or a FACS I analyzer instrument (Becton Dickinson & Co.) as described (18, 19, 27) . Negative controls were cells incubated with biotin-labeled anti-rabbit IgG followed by FITC-streptavidin, and cells incubated with second-step reagents only. Dead cells were excluded from analysis with propidium iodide. Fluorescence emitted by single viable cells was measured using logarithmic amplification. Two-color FM analysis was carried out as detailed elsewhere (18), viable cells were identified by using a combination of forward and side scatters. Thymocytes from normal BALB/c or C57BL/6 mice were used as a positive control and to set up electronical compensations for red and green fluorescence. Data from 1-5 x 10' cells were analyzed with Consort 30 software.
Immunoperoxidase Analysis. Frozen sections were cut from thymuses of both normal C57BL/6 mice and mice exposed to sublethal irradiation, placed on glass slides, fixed in acetone, and dried at -30°C. Immunoperoxidase staining was carried out as described (31) using biotinylated goat anti-rat Ig, the avidin-biotin peroxidase complex, and 3.3'-diaminobenzidine (31) . After this, the slides were stained with Giemsa and processed for microscopic examination (31) .
Results and Discussion
Development ofJoro Hybridomas. A Lewis rat was immunized with C4-77 marrow proT cells in CFA in the footpad and boosted 3 and 7 d later with these cells without adjuvant. 1 d after the last injection, the regional cells were obtained and fused with the HATresistant Ag8 .653 myeloma. Out of956 hybridomas tested, 184 produced antibodies that bound to the marrow proT clone C4-77. The latter mAbs were further screened by immunofluorescence staining and FM for their reactivity with a marrow pro-B lymphocyte done (CB/Bm7), a pre-B cell lymphoma (18 .81), a macrophage tumor line (P388D1), total thymocytes from adult mice, and mononuclear cells from 15-d-old fetal liver. Several potentially interesting mAbs were found . In Table 1 in the spleen . CD17 Scid mice had no detectable (<1%) positive cells in the marrow and 2-4% spleen cells reactive with the three Joro mAbs. Next, we studied the liver and thymus from C57BL/6 embryos. Table 2 summarizes the results of these experiments . The three Joro mAbs bound to 1-3% nucleated fetal liver Purification of Joro+ Bone Marrow Cells. To be able to study the phenotype and functional properties of Joro+ cells, we isolated these cells from the bone marrow of 3-wk-old CBA/J mice . First, we depleted bone marrow cell suspensions of irrelevant cells by treatment with a mixture of cytotoxic mAbs and complement, and then we isolated Joro+ cells using the FACS (see Materials and Methods for details) . Joro+ marrow cell preparations in which the highest degree of purification (99-99.5%) could be obtained (Fig. 2) . Phenotype of Joro+ Marrow Cells. After an incubation period at 37°C for 8-12 h, the cell sorter-purified Joro 30-8+, Joro 37-5+, and Joro 75+ cells were washed and phenotyped by FM analysis using a panel of mAbs specific for cells of the T, B, or myeloid lineages . The cell sorter-purified Joro 30-8+, Joro 37-5+, and Joro 75+ marrow cells express low levels of Thy-1, but not CD8, CD4, and CD3 T cell lineage markers . They are positive for PgP-1 and negative for IgM, B-220, Ia, and F4/80 surface markers normally expressed by cells of the B lymphocyte and the myeloid lineages . Interestingly, N7-15% of the Joro 30-8+-purified marrow cells do not bind the Joro 75 and Joro 37-5 mAbs, whereas all Joro 75+-and Joro 37-5+-purified marrow cells bind the Joro 30-8 mAb. Thus, there are at least two subsets of Joro 30-8+ marrow cells, a small subset that lacks and a larger one that expresses the molecules recognized by the Joro 37-5 and Joro 75 mAbs .
Growth Requirements ofJoro+ Marrow Cells. The proliferative responses of cell sorter-purified Joro+ marrow cells from CBA/J mice to saturating concentrations of rILs alone or in several combinations were assessed by [3 H ]thymidine uptake during the last 8 h of a 3-d culture period . rIL3 and rIIJ4 each promoted some proliferation ofJoro 30-8+, Joro 37-5+ , or Joro 75+ marrow cells, while rIIrl, rIIJ2, rIL5, rIIr6, and rIIr7 did not . The combinations of rIL3 + rIIA and rIL3 + rIIA + rllr6 gave the best responses (Fig. 3) . Confirming these results, we have been able to establish continuously proliferating clones from Joro 30-8+ and Joro 75+ marrow cells with rIL3 + rIL4 and rIL3 + rIL4 + rl1r6 (Palacios, R., and J. Samaridis, manuscript in preparation) .
Functional Potential ofJoro+ Marrow Cells In Viva The potential of cell sorter-purified Joro 30-8+, Joro 37-5+, and Joro 75+ bone marrow cells to develop into mature T and/or B lymphocytes from CBA/J mice was studied by injecting them into sublethally irradiated (350 rad) T and B cell-deficient AKR Scid mice. In this experimental system, the presence of Thy-1 .2+ and/or IgM+ lymphocytes detected by allotypespecific mAbs in the recipient AKR Scid mice (Thy-1.1, IgMd allotypes) mark T and B lymphocytes, respectively, which originate from the donor Joro+ marrow cells from CBA/J mice (Thy-1 .2, IgMJ allotypes) . Thymocyte cell suspensions from Scid mice that had received Joro 30-8+-, Joro 75+-, or Joro 37-5+-purified marrow cells contained CD4+8 -, CD4+8+, and CD4 -8+ thymocytes, a proportion of which were also CD3+ (Fig. 4, B-D) . Thymus from Scid mice that received no marrow cells did not contain such thymocyte populations (Fig. 4 A) . Mononuclear spleen cells from AKR Scid mice that received cell sorter-purified Joro+ marrow cells or no cells (control) were obtained 8-12 wk after transfer of the Joro+ marrow cells . The presence of T lymphocytes (Thy-1 .2+, CD8+, CD4+, CD3+) and B lymphocyte lineage cells (B-220+, IgMJ+) was determined by FM analysis. The data shown above were from experiments in which the best degree of purification was obtained . These cell sorter-purified Joro * marrow cell preparations were used in the experiments summarized in Table 3 and Fig. 3 . marrow cells to subject the apparent restricted potential of these cells to a more stringent test . The Joro 30-8+ marrow cell population seems to comprise both proT lymphocytes (all Joro 75*-and Joro 37-5+-purified marrow cells are Joro 30-8+) and lineage-uncommitted lymphocyte precursors. The latter conclusion is based on the following grounds : (a) Marrow cells representing the earliest stage of B cell development (before Ig gene rearrangement), i.e., pro-B lymphocytes, are Joro 30-8 negative (Fig. 1). (b) The Joro 30-8+ marrow cell population comprises at least Thus, Joro 30-8+, 37-5+, 75+ marrow subset can give rise to T lymphocytes, while Joro 30-8 +, 37-5 -, 75 -subset can generate both T and B lymphocytes. We do not know yet whether this latter subset can give rise also to myeloid cells . Experiments with the Joro 30-8+, 37-5 -, and 75 -bone marrow clones recently established in our laboratory are in progress to directly address this issue .
Cell sorter-purified Joro! marrow cells from 3-wk-old CBA/J mice (see legend to Fig. 2) or PBS alone (control) were injected intravenously into sublethally irradiated AKR Scid mice. 8-12 wk later, spleen cells from the different groups of mice were tested FM analysis for the presence of cells expressing the surface markers indicated above. The numbers are the range of positive cells observed in the four mice per group studied .
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Thymus Colonization by Joro+ Marrow Cells. To study thymus colonization by Joro+ cells, we chose the following experimental system . Normal young adult C57BL/6 mice were exposed to a sublethal dose of irradiation (600 rad) to induce a wave of thymus recolonization . As Joro+ cells are not detectable by FM analysis in thymus of young adult mice, it was possible to follow the entry of T cell progenitors into the thymus by assessing the presence of Joro+ cells in the thymus at different times post-irradiation . This was carried out daily by FM analysis during a period of 21 d and by studying three mice at each time point. (Fig. 5) , which is compatible with the view that the colonizing cells bear all three Joro surface markers. CD4+8-and CD4+8* thymocytes were observed from day 5-6, and CD4 -8+ thymocytes were detected from day 9-10 post-irradiation (Fig. 5 B, and data not shown) . These findings show that Joro+ cells enter the thymus 2 d after irradiation, where they expand during the following 4 d and undergo further differentiation.
In another experiment following the same protocol as above, the presence and the localization of Joro+ cells was determined by immunoperoxidase staining of tissue sections from both normal thymus and thymuses obtained daily during the first 8 d after sublethal irradiation of C57BL/6 mice. Very few Joro 30-8+, Joro 37-5 +, and Joro 75+ cells were found in the thymus of normal C57BL/6 mice. Virtually all Joro+ cells were in the subcapsular area and in the outer cortex, but no Joro+ cells were found in the medulla (data not shown) . The analysis of tissue sections from thymus at 2 d postirradiation showed the presence of significant numbers of Joro 30-8+, Joro 37-5+, and Joro 75+ cells. These Joro+ cells were mainly in the subcapsular area and in the outer cortex but not in the medulla, and they all exhibited a lymphoblastoid morphology. Between days 4 and 6 post-irradiation, the Joro+ cells tended to localize in the mid and deep cortex . Thymuses obtained at day 8 post-irradiation contained fewer Joro+ cells, which, like in the normal thymus, were in the subcapsular region and outer cortex. For the sake of brevity, Fig. 6 illustrates the results with some examples obtained with the Joro 37-5 antibody only. 226 Pro -T lymphocytes Thus, the immunohistochemical analysis confirms and complements the information obtained by FM analysis in a separate experiment . Taken together, the results from these experiments indicate first that there are normally very few Joro 30-8+, Joro 37-5+, and Joro 75+ lymphoid cells in the thymus of young C57BL/6 mice, and that they are preferentially in the subcapsular area and outer cortex, but not in the medulla . These Joro+ cells most probably represent recent T cell progenitor migrants from the bone marrow. Second, in the experimental system used here, the Joro+ cells seem to colonize the thymus of sublethally irradiated mice by entering via blood vessels through the subcapsular and outer cortex regions, where they proliferate and subsequently migrate to inner areas of the cortex . Most Joro+ cells must differentiate into Joro-thymocytes within the cortex, since no Joro+ cells are found in the medulla at any time, and since fewer Joro+ cells were found at day 7-8 post-irradiation . While our results are of relevance to the process of thymus repopulation in the adult mice, it remains to be determined whether this process follows a similar pattern in the mouse embryo. Concluding Remarks. The Joro mAbs described here appear to recognize cell surface determinants that are unique for early lymphocyte precursors, although we cannot exclude the possibility that they are also expressed by nonhemopoietic cells. Our results suggest that in bone marrow ofyoung mice, cells expressingJoro 30-8 are very early hematopoietic precursor cells that are either committed to the lymphocyte lineage or that are even less differentiated pluripotent cells. Commitment to T cell differentiation seems to be associated with additional expression of Joro 37-5 and Joro 75.
It should be stressed that the experiments reported here were only designed to study hematopoietic cells that bind to the Joro 30-8, Joro 37-5, andJoro 75 mAbs; hence, they do not address the issue of whether the Joro antibodies detect all precursor cells for T lymphocytes. Experiments to define it are currently underway.
Recently it was shown that a Thy-1+ Sca-1+ population of marrow cells highly enriched for pluripotent stem cells give rise to thymocytes and peripheral T lymphocytes after intravenous transfer, and that after their direct transfer into the thymus of sublethally irradiated mice, a third of these Thy-1+ Sca-1+ marrow cells grew in this organ (11) . The interpretation favored by the authors is that pluripotent stem cells as such migrate to the thymus, and that commitment to develop along the T cell pathway only takes place once the stem cell has entered this organ (11) . Our findings do not necessarily argue against this scenario, but the present results, as well as our previous studies (14, 32) , and those ofother groups (33) (34) (35) , do provide strong evidence for the existence of progenitor cells committed to the T cell lineage before migration to the thymus .
It is possible that both proT lymphocytes and pluripotent stem cells as such may colonize the thymus and generate T lymphocytes. However, because the thymus-repopulating activity of the Thy-1+ Sca-1+ marrow cell subset was assessed 14-28 d after their transfer, the possibility that Thy-1+ Sca-1+ stem cells (assuming that the isolated population comprises only pluripotent stem cells) first generated proT lymphocytes, which in turn migrated to the thymus, was not formally excluded (11) . Actually, we have preliminary evidence that stem cells generate in vitro Joro+ cells U.C. Gutierrez and R. Palacios, unpublished observations). Also, the results in the study of Sprangrude et al. (11) , showing that a third of a population of Thy-1+ Sca-1+ marrow cells (clearly highly enriched for pluripotent stem cells) grew in the thymus ofsublethally irradiated mice after theirintrathymic transfer (11) , only documents that the thymic environment of irradiated mice can support proliferation of some Thy-1+ Sca-1+ marrow cells . It does not address the issue of whether or not pluripotent stem cells as such normally migrate to the thymus via physiological routes (i.e., via blood) . Several types of T lineage cells (e.g., proT [131, CD4 -8-TCR/ CD3-thymocytes [361, CD4 -8-TCR-a/0-CD3+ T cell lines (21) , CD4+8+ thymocytes [371) with or without the capacity to repopulate the thymus via physiological routes (after intravenous transfer) grow in the thymus after intrathymic injection . Thus, we think that direct evidence is still needed to accept that pluripotent stem cells as such normally migrate and colonize the thymus . This may be feasible to address when antibodies specific for pluripotent stem cells become available, and performing kinetic studies such as those used here to study the thymus repopulating potential of the Joro+ cells .
The Joro 30-8, Joro 37-5, and Joro 75 mAbs together with recently developed in vitro systems for T cell differentiation (18) should facilitate the study of cellular and molecular events of prethymic and early intrathymic phases of T lymphocyte development . The specificity and development stage-restricted expression of the molecules recognized by these mAbs raise the possibility that they might function in early interactions of proT lymphocytes with a set of bone marrow stromal cells and thymic stromal components, perhaps as adhesion molecules or ligands involved in homing to the thymus. We shall now attempt to isolate cDNAs encoding the molecules recognized by the Joro mAbs as a complementary approach to determine their function.
